SNCA and Parkinson disease: Potential explanations of subtype differences include different PD-associated protein dysfunctions (Quinn et al., 2020; Mencke et al., 2021; Menozzi and Schapira, 2021), different accumulation rates of pathogenic alpha-synuclein (Lawton et al., 2022), different trajectories of pathology progression (De Pablo-Fernández et al., 2019) or possibly even different compensatory capacities in the neural circuits (Palermo et al., 2020; Wang et al., 2022).